Aravive Announces Pricing of Public Offering of Common Stock
November 27, 2019 08:30 ET
|
Aravive, Inc.
HOUSTON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of...
Aravive Announces Proposed Public Offering of Common Stock
November 26, 2019 17:14 ET
|
Aravive, Inc.
HOUSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), (“Aravive”) a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of...
Aravive Reports Positive Data Supporting Relationship Between AVB-500 Levels, Anti-Tumor Activity and Progression Free Survival in Women with Ovarian Cancer
November 20, 2019 07:00 ET
|
Aravive, Inc.
Statistically significant four-fold increase in progression free survival observed in women with high AVB-500 levels Aravive to Host Conference Call Today at 8 a.m. EST HOUSTON, Nov. 20, 2019 ...
Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer
November 12, 2019 08:00 ET
|
Aravive, Inc.
HOUSTON and WILMINGTON, Del., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) and AstraZeneca (NYSE: AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of...
CORRECTION – Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
November 08, 2019 13:11 ET
|
Aravive, Inc.
HOUSTON, Nov. 08, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline on Thursday, November 7th by Aravive, Inc. (Nasdaq: ARAV), please note that in the last sentence of the second...
Aravive Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Updates
November 07, 2019 16:05 ET
|
Aravive, Inc.
HOUSTON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive Announces Publication of AVB-500 Nonclinical Study in Treatment-Resistant ccRCC Animal Models in Cancer Research
October 18, 2019 08:00 ET
|
Aravive, Inc.
AVB-500 reduced tumor size and blood vessel density in animal models Study highlights role of GAS6/AXL signaling in promoting tumor angiogenesis through regulation of plasminogen receptor S100A10 ...
Aravive Presents Positive Data from Initial 12 Patients in Phase 1b Portion of its Phase 1b/2 Ovarian Cancer Study of AVB-500 in Late Breaking Oral Presentation at European Society for Medical Oncology Congress in Barcelona
September 27, 2019 10:15 ET
|
Aravive, Inc.
HOUSTON, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today presented positive data from the initial 12 patients of the ongoing Phase 1b portion of the company’s Phase 1b/2 study...
Aravive Announces Participation at the 2019 Cantor Global Healthcare Conference
September 27, 2019 08:00 ET
|
Aravive, Inc.
HOUSTON, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
Aravive to Present Late-Breaking Oral Presentation at European Society for Medical Oncology Congress 2019 in Barcelona
September 18, 2019 08:00 ET
|
Aravive, Inc.
HOUSTON, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV) today announced that its late-breaking abstract has been accepted for oral presentation in a proffered paper session at the...